HOME ·

01276.HK

HENGRUI PHARMA (01276.HK): Two Drugs Win Clinical Trial Approval in China
Tags：
HENGRUI PHARMA01276.HKClinical Trial
2026-09-22
HENGRUI PHARMA (01276.HK): SHR-4595 Gets Clinical Trial Approval in China
Tags：
HENGRUI PHARMA01276.HKClinical Trial
2026-09-22
HENGRUI PHARMA (01276.HK): Makes A-Share Repurchase of 335,000 Shares for RMB 14,503,550
Tags：
HENGRUI PHARMA01276.HKBuyback
2026-09-17
HENGRUI PHARMA (01276.HK): HRS-4139 Tablets Cleared for Clinical Trial in Moderate-to-Severe Plaque Psoriasis
Tags：
NewTimeSpaceHENGRUI PHARMA01276.HK
2026-09-16
HENGRUI PHARMA (01276.HK): Recaticimab Cleared for Clinical Trials, Phase III Study Planned in Stroke Recurrence
Tags：
NewTimeSpaceHENGRUI PHARMA01276.HK
2026-09-16
HENGRUI PHARMA (01276.HK): Marketing Application for Class 1 Innovative Drug SHR-2004 Injection Accepted by NMPA for VTE Prevention After Knee Replacement Surgery
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-09-14
HENGRUI PHARMA (01276.HK): HER3 ADC Ruzaltatug Rezetecan granted breakthrough therapy designation
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-09-11
HENGRUI PHARMA (01276.HK): Hetrombopag Olamine Tablets approved for two additional indications, becoming world's first TPO-RA approved for CTIT
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-09-10
HENGRUI PHARMA (01276.HK): NMPA Accepts Marketing Application for Ruippotipeptide Injection for Adults with Type 2 Diabetes
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-09-09
HENGRUI PHARMA (01276.HK): Clinical trials approved for HRS-6209 capsules and HRS-4508 tablets in advanced breast cancer and solid tumors
Tags：
HENGRUI PHARMA01276.HKClinical Trial
2026-09-07
HENGRUI PHARMA (01276.HK): HRS-1597 tablets approved for clinical trial for weight management
Tags：
HENGRUI PHARMA01276.HKClinical Trial
2026-09-07
HENGRUI PHARMA (01276.HK): SHR-1179 injection approved for clinical trial, targeting weight management indication
Tags：
HENGRUI PHARMA01276.HKClinical Trial
2026-09-07
HENGRUI PHARMA (01276.HK): NMPA approves oteseconazole capsules for marketing in China for severe vulvovaginal candidiasis
Tags：
HENGRUI PHARMA01276.HKDrug Marketing Authorization
2026-09-04
HENGRUI PHARMA (01276.HK): NMPA accepts marketing application for atopic dermatitis antibody Zhuotuoqibai injection
Tags：
HENGRUI PHARMA01276.HKNew Drug Marketing Application
2026-09-04
HENGRUI PHARMA (01276.HK): NMPA accepts marketing application for oral GLP-1 weight-loss drug HRS-7535 tablets
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-09-04
Hengrui Pharmaceuticals (01276.HK): NDA for HRG2010 Capsules Accepted
Tags：
Hengrui Pharmaceuticals01276.HK
2026-08-25
HENGRUI PHARMA (01276.HK): SHR-7012 Injection Receives Clinical Trial Approval for Treating Cutaneous Lupus Erythematosus
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-08-20
HENGRUI PHARMA(01276.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 4.47 billion, YoY increase of 0.34%
Tags：
HENGRUI PHARMA01276.HKprofit
2026-08-20
HENGRUI PHARMA (01276.HK): Proposes Adoption of 2026 H-Share Scheme with Mandate Limit of Not More Than 1,000,000 H Shares
Tags：
HENGRUI PHARMA01276.HKShare Scheme
2026-08-19
HENGRUI PHARMA (01276.HK): SHR-7590 Injection Receives Drug Clinical Trial Approval Notice for Ulcerative Colitis and Crohn's Disease
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-08-12
123